Hostname: page-component-74656f9884-2dmjx Total loading time: 0 Render date: 2026-11-07T22:59:06.753Z Has data issue: false hasContentIssue false

Effects of inhibiting PI3K-Akt-mTOR pathway on lipid metabolism homeostasis in goose primary hepatocytes

Published online by Cambridge University Press:  09 March 2016

D. D. Liu
Affiliation:
Institute of Animal Breeding & Genetics, Sichuan Agricultural University, Chengdu, Sichuan 611130, People’s Republic of China
C. C. Han*
Affiliation:
Institute of Animal Breeding & Genetics, Sichuan Agricultural University, Chengdu, Sichuan 611130, People’s Republic of China
H. F. Wan
Affiliation:
Institute of Animal Breeding & Genetics, Sichuan Agricultural University, Chengdu, Sichuan 611130, People’s Republic of China
F. He
Affiliation:
Institute of Animal Breeding & Genetics, Sichuan Agricultural University, Chengdu, Sichuan 611130, People’s Republic of China
H. Y. Xu
Affiliation:
Institute of Animal Breeding & Genetics, Sichuan Agricultural University, Chengdu, Sichuan 611130, People’s Republic of China
S. H. Wei
Affiliation:
Institute of Animal Breeding & Genetics, Sichuan Agricultural University, Chengdu, Sichuan 611130, People’s Republic of China
X. H. Du
Affiliation:
Institute of Animal Breeding & Genetics, Sichuan Agricultural University, Chengdu, Sichuan 611130, People’s Republic of China
F. Xu
Affiliation:
Institute of Animal Breeding & Genetics, Sichuan Agricultural University, Chengdu, Sichuan 611130, People’s Republic of China

Abstract

Phosphatidylinositol-3 kinases (PI3K)-Protein kinase B (Akt)-mammalian target of rapamycin (mTOR) pathway plays an important role in the synthesis and secretion of triacylglycerol. However, the mechanism of PI3K-Akt-mTOR pathway in regulating lipid metabolism of goose liver was poorly understood. The purpose of this study was to determine how PI3K-Akt-mTOR pathway regulating lipid metabolic homeostasis in goose hepatocytes. Goose primary hepatocytes were treated with different PI3K-Akt-mTOR signal inhibitors (LY294002, rapamycin and NVP-BEZ235) for 24 h. The results showed that these inhibitors evidently inhibited PI3K-Akt-mTOR downstream signaling. Meanwhile, these PI3K-Akt-mTOR inhibitors reduced intracellular lipid accumulation, decreased the mRNA expression and protein content of genes involved in the de novo fatty acid synthesis, while increased the transcriptional and protein level of key factors involved in fatty acid oxidation and very low density lipoprotein (VLDL) assembly and secretion. Conclusion: These findings suggested that the reduction of lipids accumulation induced-by inhibiting PI3K-Akt-mTOR pathway was closely linked to the decrease of lipogenesis, the increase of fatty acids oxidation, and the increase of VLDL assembly and secretion in goose hepatocytes.

Information

Type
Research Article
Copyright
© The Animal Consortium 2016 
Figure 0

Table 1 Primer sequences for real-time PCR

Figure 1

Figure 1 Cell viability was examined by MTT assay after treatment LY294002, rapamycin or NVP-BEZ235. LY=LY294002; rapa=rapamycin; NVP=NVP-BEZ235.

Figure 2

Figure 2 The effects of LY294002, rapamycin and NVP-BEZ235 on activation of PI3K-Akt-mTOR pathway in hepatocytes. (a) The mRNA expression (PI3K, Akt, mTOR, raptor) by Real-Time PCR, (b) protein expression (PI3K, Akt, mTOR, S6K) by ELISA kits; (c) protein expression of S6K and P-S6K by western blotting. The different letters indicated significant differences (P<0.05). LY=LY294002; rapa=rapamycin; NVP=NVP-BEZ235.

Figure 3

Figure 3 The effects of LY294002, rapamycin and NVP-BEZ235 on intracellular lipid accumulation in hepatocytes. (a) After Oil red O staining, intracellular lipid accumulation by Phase-contrast microscopy at a magnification of 200×. (b) After Oil red O extraction, intracellular lipid accumulation by monitoring OD value at 510 nm. The different letters indicated significant differences (P<0.05). LY=LY294002; rapa=rapamycin; NVP=NVP-BEZ235.

Figure 4

Figure 4 The effects of LY294002, rapamycin and NVP-BEZ235 on mRNA expression of lipogenic genes (SREBP-1c, ChREBP, FAS, ACCα, LXRα) in hepatocytes. The different letters indicated significant differences (P<0.05). LY=LY294002; rapa=rapamycin; NVP=NVP-BEZ235.

Figure 5

Figure 5 The effects of LY294002, rapamycin and NVP-BEZ235 on protein contents of ACCα and FAS in hepatocytes. (a) Protein contents of ACCα and FAS using ELISA kits; (b) protein contents of ACCα using western blotting. The different letters indicated significant differences (P<0.05). LY=LY294002; rapa=rapamycin; NVP=NVP-BEZ235; 1: control group, 2: 20 μmol/l LY294002, 3: 30 nmol/l rapamycin, 4 : 1 μmol/l NVP-BEZ235.

Figure 6

Figure 6 The effects of LY294002, rapamycin and NVP-BEZ235 on fatty acid oxidation in hepatocytes. (a) mRNA expression of PPARγ, PPARα and CPT-1 by Real-Time PCR; (b) protein content of CPT-1 by ELISA kits. The different letters indicated significant differences (P<0.05). LY: LY294002; rapa=rapamycin; NVP=NVP-BEZ235.

Figure 7

Figure 7 The effects of LY294002, rapamycin and NVP-BEZ235 on VLDL assembly and secretion in hepatocytes. (a) mRNA expression of MTTP, FoxO1, ApoB by Real-Time PCR; (b) intracellular VLDL concentration by ELISA kits. The different letters indicated significant differences (P<0.05). LY=LY294002; rapa=rapamycin; NVP=NVP-BEZ235; VLDL=very low density lipoprotein.